Other Vaccines - Europe

Europe

Highlights

In Europe, the revenue in the Other Vaccines market is forecasted to reach US$9.04bn in 2024.
It is expected to exhibit a compound annual growth rate (CAGR 2024-2029) of 10.25%, leading to a market volume of US$14.73bn by 2029.
When compared globally, United States is projected to generate the highest revenue of US$24.73bn in 2024.
In Europe, there is a growing demand for other vaccines, with countries like Germany and France leading the way in research and development.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The Other Vaccines market in Europe has been experiencing steady growth in recent years, driven by a number of factors including increasing awareness of the importance of vaccination, rising healthcare expenditure, and government initiatives to improve access to healthcare services.

Customer preferences: Customers in Europe are increasingly prioritizing preventative healthcare measures, including vaccination, as a means of maintaining good health and preventing the spread of infectious diseases. This trend is particularly evident in countries with high levels of healthcare spending and well-established healthcare systems, where access to vaccines is readily available and public awareness campaigns have been successful in promoting the benefits of vaccination.

Trends in the market: One trend that has been observed in the Other Vaccines market in Europe is the increasing demand for combination vaccines, which offer protection against multiple diseases in a single shot. This trend is being driven by a number of factors, including the convenience of receiving multiple vaccinations in a single visit, the reduced cost of administering combination vaccines compared to individual vaccines, and the potential for improved patient compliance with vaccination schedules.Another trend in the market is the growing use of vaccines for non-traditional indications, such as cancer prevention and treatment. This trend is being driven by advances in vaccine technology and a greater understanding of the role that vaccines can play in preventing and treating a range of diseases beyond infectious diseases.

Local special circumstances: In countries with high levels of healthcare spending and well-established healthcare systems, such as Germany and France, the Other Vaccines market is well-developed and characterized by a high level of competition among vaccine manufacturers. In these markets, customers have a wide range of options when it comes to choosing vaccines, and manufacturers must differentiate themselves through product innovation and marketing campaigns.In countries with less well-developed healthcare systems, such as those in Eastern Europe, the Other Vaccines market is still emerging, and there is significant potential for growth as healthcare infrastructure and awareness of the importance of vaccination continue to improve.

Underlying macroeconomic factors: The growth of the Other Vaccines market in Europe is being driven by a range of macroeconomic factors, including increasing healthcare expenditure, rising demand for preventative healthcare measures, and government initiatives to improve access to healthcare services. Additionally, the market is being shaped by advances in vaccine technology, which are enabling the development of new vaccines for a range of indications beyond infectious diseases. Overall, the outlook for the Other Vaccines market in Europe is positive, with strong growth expected to continue in the coming years.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.